Asia Pacific Bioreactors Market size crossed USD 1.3 billion in 2021 and is anticipated to showcase around 14.5% growth rate between 2022 and 2028.
Bioreactors offer enormous potential in the development of vaccines & other medicines used to combat the global spread of COVID-19 and other infectious disorders. The increasing requirement from governmental vaccination programs and private entities to vaccine large sections of the population requires scientists to work under pressure to shorten the time-to-market.
Get more details on this report - Request Free Sample PDF
Innovations in single-use bioreactors will offer momentous growth opportunities to Asia Pacific market. These advancements include remote monitoring of culture process, continuous manufacturing, integration of analytical technology, and single-use systems.
Impact of COVID-19 outbreak on Asia Pacific bioreactors market outlook
The COVID-19 pandemic strained global healthcare systems and disrupted the supply chains. It necessitated the development of vaccinations and monoclonal antibodies for the prevention and treatment of the devastating disease, as well as other autoimmune conditions. A large amount of investments are made toward research into cell culture media created in bioreactors. The need for appropriate immunizations and pharmaceutical products is projected to boost the Asia Pacific bioreactors business outlook, as the global threat of infectious and chronic diseases grows.
Asia Pacific Market, By Product Type
The Asia Pacific reusable bioreactors market share is expected to be more than 70% by 2028. Reusable stainless-steel bioreactors have fixed vessel configurations with predefined port assemblies. They assist in the production of vaccines and drugs at a larger volume and scale. These bioreactors are increasingly used large-scale production runs in numerous biologics and pharmaceuticals manufacturers and contract manufacturing organizations in nations such as China and India.
Asia Pacific Market, By Cell
Mammalian cells are widely used in bioprocessing viral vaccines, medicines, and diagnostic proteins. They are also used in research. The fundamental benefits of mammalian cell expression are that the signals for eukaryotic protein synthesis, processing, and secretion are accurately and effectively recognized. Although antibody production via mammalian cells is more challenging, the main advantage is that the antibody will be as near to native structure as feasible, offering good binding activity.
Asia Pacific Bioreactors Market, By Cell
The stem cells segment will exhibit a CAGR of 14% during the forecast period, owing to rising number of research activities to develop stem cell therapy for a wide range of applications including regenerative medicine and aesthetic medicine. The Indian biotech sector grew by 14% with investments in R&D trebling to USD 1.02 billion in 2021 from USD 320 million in 2020, according to a report released by the country’s Department of Biotechnology.
Asia Pacific Market, By End-use
Adoption of bioreactors in CMOs will expand during the analysis period. Numerous companies based in the developed countries outsource manufacturing activities to Asian countries owing to cost advantage. With growing need for cost containment, increasing number of CMOs in the region, the demand for bioreactors will surge over the forthcoming years. The presence of major companies in the region will serve to be high impacting factor for product consumption.
Competitive Industry Landscape
Major players involved in the Asia Pacific bioreactors market include Cytiva, Sartorius Stedim Biotech, Merck, Eppendorf AG, and Thermo Fisher Scientific. These companies are undertaking various strategies such as product launch and collaborations to strengthen their market position. Catering to the high demand for large-scale single-use systems, Thermo Fisher Scientific announced the launch of HyPerforma DynaDrive 5,000 L and HyPerforma DynaDrive 3,000 L single-use bioreactors in March 2021.